158 related articles for article (PubMed ID: 22464845)
21. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
23. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
24. Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force.
Balis FM; Womer RB; Berg S; Winick N; Adamson PC; Fox E;
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28509433
[TBL] [Abstract][Full Text] [Related]
25. [Level of evidence for therapeutic drug monitoring of carboplatin].
Hulin A; Chatelut E; Royer B; Le Guellec C;
Therapie; 2010; 65(3):157-62. PubMed ID: 20699065
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.
Hutson JR; Weitzman S; Schechter T; Arceci RJ; Kim RB; Finkelstein Y
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):709-22. PubMed ID: 22509821
[TBL] [Abstract][Full Text] [Related]
27. The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer.
Burke GA; Estlin EJ; Lowis SP
Cancer Treat Rev; 1999 Feb; 25(1):13-27. PubMed ID: 10212587
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy dosing part II: alternative approaches and future prospects.
Kaestner SA; Sewell GJ
Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):99-107. PubMed ID: 17355104
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
30. Disposition of antineoplastic agents in the very young child.
McLeod HL; Relling MV; Crom WR; Silverstein K; Groom S; Rodman JH; Rivera GK; Crist WM; Evans WE
Br J Cancer Suppl; 1992 Aug; 18():S23-9. PubMed ID: 1503923
[TBL] [Abstract][Full Text] [Related]
31. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
[TBL] [Abstract][Full Text] [Related]
32. Utility of individualized carboplatin dosing alone and in combination regimens.
Egorin MJ; Jodrell DI
Semin Oncol; 1992 Feb; 19(1 Suppl 2):132-8. PubMed ID: 1411624
[TBL] [Abstract][Full Text] [Related]
33. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
34. Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management.
Mahmud F; Chung SW; Alam F; Choi JU; Kim SW; Kim IS; Kim SY; Lee DS; Byun Y
J Control Release; 2017 Mar; 249():42-52. PubMed ID: 28093298
[TBL] [Abstract][Full Text] [Related]
35. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer.
Chintagumpala M; Blaney SM; Bomgaars LR; Aleksic A; Kuttesch JF; Klenke RA; Berg SL
J Clin Oncol; 2004 Nov; 22(21):4394-400. PubMed ID: 15514381
[TBL] [Abstract][Full Text] [Related]
37. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Lambert MP; Shields C; Meadows AT
Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
[TBL] [Abstract][Full Text] [Related]
39. [Role of individualized dosing in oncology: are we there yet?].
Joerger M
Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
[TBL] [Abstract][Full Text] [Related]
40. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
